Merck

VastBiome is a biotechnology company that mines microbiome drugs to treat cancer and autoimmune disease. The company employs its proprietary methods in genomic sequencing, artificial intelligence, and synthetic biology to discover biomarkers and therapeutics for challenging immunologic disorders. It offers a platform that aims to aggregate public and private data in order to generate a microbiome database and leverages analytical processes to discover connections between distinct and biologically related data in order to increase statistical power and drive discovery. In addition, the platform can be used to identify novel biomarkers to risk-stratify patients and predict clinical outcomes. It was co-founded by Peter McCaffrey, Kovi Bessoff, Ayin Vala, and Kareem Barghouti in Millbrae, California in 2018.

Qure.ai Technologies Private Limited specializes in developing artificial intelligence software for the healthcare sector, focusing on medical imaging to enhance disease diagnosis from radiology and pathology images. Founded in 2016 and headquartered in Mumbai, India, with a presence in New York, the company offers tools such as qXR, which automates chest X-ray interpretation to identify abnormal findings, including signs of tuberculosis. Qure.ai also provides qER, which assists in triaging critical head CT scans and offers tools for monitoring traumatic brain injury and reporting. By leveraging deep learning solutions, Qure.ai aims to improve the accuracy of diagnoses and make healthcare more affordable and accessible, ultimately allowing healthcare professionals to dedicate more time to patient care.

Koneksa Health Inc. is a healthcare data analytics company based in New York, with an additional location in London. Founded in 2013, the company specializes in designing and developing software for pharmaceutical and biotech firms to facilitate decision-making and regulatory claims based on remotely generated patient data. Its flagship product, Koneksa Compare, provides a dashboard for capturing, monitoring, and analyzing patient-generated data and outcomes in clinical studies. The software supports the integration of emerging technologies, such as bio-sensors, activity trackers, and mobile-based questionnaires, allowing researchers to expand the range of analyzable data and reduce subjectivity in clinical endpoints. Koneksa Health aims to enhance the efficiency and accuracy of clinical research through its innovative solutions.

Verana Health, Inc. is a software company dedicated to improving the connection between healthcare providers and mobile diagnostics. Based in San Francisco, the company provides a range of tools designed to facilitate real-time access to diagnostic data for both patients and physicians. Its flagship product, SightBook, is a mobile application that allows users to assess their vision and share results with their healthcare providers instantly, while also enabling physicians to manage appointments and treatments effectively. In addition to SightBook, Verana Health offers a cloud-based portal, a smartphone application for vision assessments, mobile imaging devices, and analytics tools that support the monitoring of patient data. By partnering with leading medical associations, Verana Health transforms clinical data into actionable insights, helping to accelerate medical research and improve patient care. The company was previously known as Digisight Technologies, Inc. before rebranding in July 2018 and has been operational since its incorporation in 2008.

PreciseDx is a company specializing in cancer risk stratification by providing patient-specific risk assessments through the analysis of morphological features. Utilizing artificial intelligence and its proprietary Morphology Feature Array™, PreciseDx develops disease-specific assays that offer detailed insights into each patient's risk profile and potential outcomes, thereby enhancing treatment decision-making. The company combines its clinical, regulatory, and translational research expertise to advance technologies in areas such as clinical modeling, patient phenotyping, and image analysis, ultimately aiming to improve patient outcomes and quality of life in the realm of cancer and other diseases.

Antidote Technologies Ltd. operates as a digital health company. The company offers Antidote Match that helps patients to identify matching trials; Connect Network that streams the information to patients; and Antidote Bridge that allows adding details about studies to the available information. It serves medical researchers, pharmaceutical companies, and patient organizations. Antidote Technologies Ltd. was formerly known as TrialReach Ltd. and changed its name to Antidote Technologies Ltd. in September 2016. The company was founded in 2009 and is based in London, United Kingdom.

PathAI, Inc. develops artificial intelligence-based technology solutions for pathology laboratories. It develops a technology that assists pathologists in making rapid and accurate diagnoses for patients. The company also builds solutions to help identify patients that benefit from novel therapies, to make scalable personalized medicine a reality. PathAI, Inc. was founded in 2016 and is based in Boston, Massachusetts with an additional office in Austin, Texas.

M2Gen® is a health informatics solutions company focused on accelerating the discovery, development and delivery of personalized medicine. Our Company was founded in 2006 at the Moffitt Cancer Center to operationalize the Total Cancer Care® Protocol, a unique approach to studying patients throughout their lifetime. In this effort, we partner with the nation’s leading cancer centers via the Oncology Research Information Exchange Network (ORIEN).

VastBiome is a biotechnology company that mines microbiome drugs to treat cancer and autoimmune disease. The company employs its proprietary methods in genomic sequencing, artificial intelligence, and synthetic biology to discover biomarkers and therapeutics for challenging immunologic disorders. It offers a platform that aims to aggregate public and private data in order to generate a microbiome database and leverages analytical processes to discover connections between distinct and biologically related data in order to increase statistical power and drive discovery. In addition, the platform can be used to identify novel biomarkers to risk-stratify patients and predict clinical outcomes. It was co-founded by Peter McCaffrey, Kovi Bessoff, Ayin Vala, and Kareem Barghouti in Millbrae, California in 2018.

Koneksa Health Inc. is a healthcare data analytics company based in New York, with an additional location in London. Founded in 2013, the company specializes in designing and developing software for pharmaceutical and biotech firms to facilitate decision-making and regulatory claims based on remotely generated patient data. Its flagship product, Koneksa Compare, provides a dashboard for capturing, monitoring, and analyzing patient-generated data and outcomes in clinical studies. The software supports the integration of emerging technologies, such as bio-sensors, activity trackers, and mobile-based questionnaires, allowing researchers to expand the range of analyzable data and reduce subjectivity in clinical endpoints. Koneksa Health aims to enhance the efficiency and accuracy of clinical research through its innovative solutions.

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical development company focused on creating immunotherapies for various human diseases. Established in 2014 and headquartered in Sioux Falls, South Dakota, with an additional office in Cambridge, Massachusetts, the company utilizes advanced antibody science to develop large-scale production platforms for immunoglobulins. Its product pipeline includes SAB-142, which targets Type 1 diabetes; SAB-176 for seasonal influenza; and SAB-301 aimed at Middle East Respiratory Syndrome Coronavirus (MERS-CoV). SAB Biotherapeutics is committed to addressing public health challenges, rare conditions, long-term diseases, and potential global pandemic threats through innovative therapeutic solutions.

Syapse, Inc. is a company that specializes in precision medicine through its software platform, which integrates and analyzes clinical, molecular, treatment, and outcomes data. This platform supports data-driven decision-making for healthcare executives, care teams, and researchers involved in precision medicine programs. One of its key offerings is the Syapse Learning Health Network, a global data-sharing network focused on oncology, which leverages real-world data to enhance clinical decision-making. By connecting health systems, life sciences companies, and regulators, Syapse aims to accelerate the generation of real-world evidence to improve cancer patient outcomes. Founded in 2008 and headquartered in San Francisco, California, Syapse is committed to ensuring that all cancer patients receive high-quality care through improved precision medicine initiatives.

PathAI, Inc. develops artificial intelligence-based technology solutions for pathology laboratories. It develops a technology that assists pathologists in making rapid and accurate diagnoses for patients. The company also builds solutions to help identify patients that benefit from novel therapies, to make scalable personalized medicine a reality. PathAI, Inc. was founded in 2016 and is based in Boston, Massachusetts with an additional office in Austin, Texas.

CIOX Health, LLC is a healthcare services company based in Alpharetta, Georgia, specializing in the management and exchange of health information. The firm operates a cloud-based platform that digitizes and organizes both structured and unstructured medical records, facilitating access to clinical data for various stakeholders, including healthcare providers, health plans, and government agencies. CIOX offers a range of services including information release, medical record retrieval, coding and education, and risk adjustment solutions. Their expertise is designed to improve patient outcomes while ensuring compliance with regulations regarding the release of medical information. CIOX Health serves a diverse clientele, including hospitals, physician practices, law firms, and life insurance companies, making it a key player in the healthcare information management sector. The company was established in 1976 and operates additional locations in Phoenix, Arizona, and Green Bay, Wisconsin.

Mesentech Inc. is a regenerative medicine company based in Vancouver, Canada, that specializes in developing novel drug conjugates for targeted bone therapy. Founded in 2013, the company utilizes a proprietary prodrug platform that selectively delivers therapeutics to bone, addressing challenging medical conditions such as osteoporosis and Duchenne muscular dystrophy. Its lead product, MES1007, is a bone-targeted prodrug of a prostaglandin mimetic designed to reverse bone loss by effectively targeting mesenchymal stem cells. This innovative approach enables the delivery of active pharmaceutical agents directly to the bone, minimizing systemic side effects often associated with high-dose treatments. Pre-clinical in-vivo models have validated the efficacy of Mesentech's technology, positioning the company to advance treatments for low-bone-density disorders and improve outcomes in bone healing and regeneration.

Mesentech Inc. is a regenerative medicine company based in Vancouver, Canada, that specializes in developing novel drug conjugates for targeted bone therapy. Founded in 2013, the company utilizes a proprietary prodrug platform that selectively delivers therapeutics to bone, addressing challenging medical conditions such as osteoporosis and Duchenne muscular dystrophy. Its lead product, MES1007, is a bone-targeted prodrug of a prostaglandin mimetic designed to reverse bone loss by effectively targeting mesenchymal stem cells. This innovative approach enables the delivery of active pharmaceutical agents directly to the bone, minimizing systemic side effects often associated with high-dose treatments. Pre-clinical in-vivo models have validated the efficacy of Mesentech's technology, positioning the company to advance treatments for low-bone-density disorders and improve outcomes in bone healing and regeneration.

ConnectedMed builds digital therapeutics platform that allows patients to manage their primary and chronic care needs.

TriNetX, Inc. is a global health research network that facilitates collaboration among healthcare organizations, biopharmaceutical companies, and contract research organizations. The company provides a platform that enables researchers to analyze patient populations and derive real-world evidence, thereby enhancing trial design and improving site selection. Key offerings include TriNetX Live, a cloud-based solution for real-time analytics; TriNetX Research, which delivers longitudinal clinical data; and TriNetX Download, a platform for accessing real-world clinical data. Additionally, TriNetX features Attract Trials for data alignment in collaboration, Natural Language Processing for extracting clinical insights from physician documentation, and specialized tools for oncology research. Established in 2013 and headquartered in Cambridge, Massachusetts, TriNetX also has offices in Sydney, London, and Sao Paulo, and maintains compliance with HIPAA and GDPR regulations.

Clinithink Ltd is a healthcare software company based in Bridgend, United Kingdom, that specializes in cloud-based data analytics solutions. Founded in 2009, the company has developed a platform known as CLiX, which employs Natural Language Processing (NLP) to convert unstructured clinical narratives into structured data. This technology allows healthcare providers, pharmaceutical companies, and content vendors to collect and analyze clinical trial data effectively. Clinithink's products include CLiX ENRICH, which facilitates the indexing and recording of clinical trial data in a preferred narrative format, and CLiX RARE, aimed at diagnosing genetic disorders in newborns. Through its innovative approach, Clinithink supports healthcare applications in data analytics, coding, and decision-making.

Immune Design Corp. (IDC) uses breakthrough technology to develop safe and effective vaccines and therapeutics, with emphasis on the prevention and treatment of infectious disease. This goal is being achieved through dedicated research aimed towards a greater understanding of the immune system, and by developing a new generation of immune-based products for the pharmaceutical industry. IDC is passionate about its mission to alleviate human suffering and pursues this goal with high energy and an unsurpassed standard of excellence

Livongo Health, Inc. is a consumer digital health company based in Mountain View, California, that offers an integrated suite of solutions aimed at improving the management of chronic conditions. Founded in 2008, Livongo focuses on empowering individuals with conditions such as diabetes, hypertension, and behavioral health issues through real-time data capture and data-driven insights. The company provides cellular-connected devices, supplies, informed coaching, and access to medications, all designed to facilitate health behavior changes. Its product offerings include specialized programs for diabetes, hypertension, prediabetes and weight management, as well as behavioral health support. Livongo's innovative approach combines technology with personalized support, aiming to enhance both clinical outcomes and the overall experience for users and their healthcare teams. As of October 2020, Livongo operates as a subsidiary of Teladoc Health, Inc.

Prognos Health is a prominent health tech company specializing in healthcare analytics aimed at improving disease management and treatment decision-making. Its platform, prognosFACTOR, allows users to quickly query billions of lab and health records from over 325 million de-identified patients, significantly reducing the time needed to answer critical healthcare questions. The Prognos Registry serves as the largest source of clinical diagnostics information across more than 30 disease areas, encompassing over 5 billion medical records for 100 million patients. By employing a suite of 500 proprietary clinical algorithms, Prognos facilitates earlier patient identification, enhancing treatment decisions and risk management. The company collaborates with key stakeholders in the healthcare ecosystem, including pharmaceutical manufacturers and payers, providing HIPAA-compliant patient-centric data through the Prognos Marketplace for various applications such as cohort design and health outcomes analysis.

Syapse, Inc. is a company that specializes in precision medicine through its software platform, which integrates and analyzes clinical, molecular, treatment, and outcomes data. This platform supports data-driven decision-making for healthcare executives, care teams, and researchers involved in precision medicine programs. One of its key offerings is the Syapse Learning Health Network, a global data-sharing network focused on oncology, which leverages real-world data to enhance clinical decision-making. By connecting health systems, life sciences companies, and regulators, Syapse aims to accelerate the generation of real-world evidence to improve cancer patient outcomes. Founded in 2008 and headquartered in San Francisco, California, Syapse is committed to ensuring that all cancer patients receive high-quality care through improved precision medicine initiatives.

Antidote Technologies Ltd. operates as a digital health company. The company offers Antidote Match that helps patients to identify matching trials; Connect Network that streams the information to patients; and Antidote Bridge that allows adding details about studies to the available information. It serves medical researchers, pharmaceutical companies, and patient organizations. Antidote Technologies Ltd. was formerly known as TrialReach Ltd. and changed its name to Antidote Technologies Ltd. in September 2016. The company was founded in 2009 and is based in London, United Kingdom.

CareSync is a prominent provider of software and services focused on chronic disease management. The company integrates technology with round-the-clock nursing services to enhance care coordination among patients, families, caregivers, and healthcare providers. CareSync offers comprehensive Chronic Care Management services, along with a software-only option, enabling healthcare practices of any size to comply with billing requirements for chronic care codes. Its certified technology also helps providers achieve Meaningful Use 2 standards for data exchange and timely access to health information. By centralizing records from various providers, CareSync allows for the secure storage and organization of health information, making it easily accessible for caregivers and healthcare professionals. This patient-centered approach empowers individuals with access to their health information and actionable goals, leading to more effective medical appointments and improved health outcomes.

Livongo Health, Inc. is a consumer digital health company based in Mountain View, California, that offers an integrated suite of solutions aimed at improving the management of chronic conditions. Founded in 2008, Livongo focuses on empowering individuals with conditions such as diabetes, hypertension, and behavioral health issues through real-time data capture and data-driven insights. The company provides cellular-connected devices, supplies, informed coaching, and access to medications, all designed to facilitate health behavior changes. Its product offerings include specialized programs for diabetes, hypertension, prediabetes and weight management, as well as behavioral health support. Livongo's innovative approach combines technology with personalized support, aiming to enhance both clinical outcomes and the overall experience for users and their healthcare teams. As of October 2020, Livongo operates as a subsidiary of Teladoc Health, Inc.

OpGen, Inc. is a precision medicine company based in Gaithersburg, Maryland, that specializes in developing molecular diagnostics and informatics aimed at combating infectious diseases. The company offers a range of products, including the Acuitas AMR Gene Panel, which detects bacterial nucleic acids and antimicrobial resistance markers, and QuickFISH and PNA FISH tests for identifying pathogens in blood cultures. Additionally, OpGen provides the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient data to help manage multidrug-resistant organisms in healthcare settings. Through its strategic collaboration with the New York State Department of Health, OpGen is working on solutions to detect and manage antimicrobial-resistant infections in healthcare facilities. The company's innovative technologies are utilized by academic, government, and research institutions globally for applications such as strain typing and genome assembly. OpGen aims to enhance patient care and outcomes while addressing the growing challenge of antibiotic resistance.

MedCPU Inc. develops real-time enterprise decision support software aimed at enhancing clinical care in hospitals across the United States. Founded in 2008 and based in New York, the company offers the medCPU Advisor platform, which integrates patient profiles derived from both structured and unstructured data. Its innovative Advisor Button technology captures and analyzes clinical information from clinicians’ free-text notes, dictations, and structured documentation entered into electronic medical records (EMRs). This analysis is conducted against an extensive library of medical content, allowing the platform to generate precise, real-time prompts for care consideration, as well as providing clinical and compliance guidance. MedCPU's focus is on improving decision-making processes in healthcare settings through advanced data integration and analysis.

Livongo Health, Inc. is a consumer digital health company based in Mountain View, California, that offers an integrated suite of solutions aimed at improving the management of chronic conditions. Founded in 2008, Livongo focuses on empowering individuals with conditions such as diabetes, hypertension, and behavioral health issues through real-time data capture and data-driven insights. The company provides cellular-connected devices, supplies, informed coaching, and access to medications, all designed to facilitate health behavior changes. Its product offerings include specialized programs for diabetes, hypertension, prediabetes and weight management, as well as behavioral health support. Livongo's innovative approach combines technology with personalized support, aiming to enhance both clinical outcomes and the overall experience for users and their healthcare teams. As of October 2020, Livongo operates as a subsidiary of Teladoc Health, Inc.

GenomeDx discovers, develops, and commercializes genomic-based laboratory tests for the personalized medicine revolution in cancer care. In partnership with physicians and scientists from leading academic medicine institutions, our mission is to bring cost-effective and high-resolution genomics for routine clinical use in cancer medicine.

WellDoc, Inc. is a digital health company focused on chronic disease management, particularly diabetes care. Founded in 2005 and headquartered in Baltimore, Maryland, WellDoc offers innovative solutions such as the DiabetesManager platform and BlueStar mobile prescription therapy. The DiabetesManager platform facilitates patient-provider coordination through features like personalized coaching, medication reminders, and real-time alerts, while BlueStar offers patients immediate guidance to enhance self-management of diabetes. WellDoc’s services also include clinical decision support for healthcare professionals and a comprehensive suite of technical services, such as software development and regulatory management. The company aims to improve health outcomes and reduce healthcare costs by integrating behavioral and motivational applications with everyday technology. WellDoc serves a diverse range of clients, including payors, employers, pharmaceutical and medical device companies, and healthcare providers.

CareSync is a prominent provider of software and services focused on chronic disease management. The company integrates technology with round-the-clock nursing services to enhance care coordination among patients, families, caregivers, and healthcare providers. CareSync offers comprehensive Chronic Care Management services, along with a software-only option, enabling healthcare practices of any size to comply with billing requirements for chronic care codes. Its certified technology also helps providers achieve Meaningful Use 2 standards for data exchange and timely access to health information. By centralizing records from various providers, CareSync allows for the secure storage and organization of health information, making it easily accessible for caregivers and healthcare professionals. This patient-centered approach empowers individuals with access to their health information and actionable goals, leading to more effective medical appointments and improved health outcomes.

cCAM Biotherapeutics Ltd., a clinical stage company, engages in the discovery and development of novel immunotherapies to treat cancer. It offers CM-24, a humanized anti CEACAM1 monoclonal antibody that inhibits the immunosuppressive effect of CEAC AM1 for the treatment of advanced or recurrent malignancies, including melanoma, non-small-cell lung, bladder, gastric, colorectal, and ovarian cancers. cCAM Biotherapeutics Ltd. was founded in 2010 and is based in Misgav, Israel. As of July 31, 2015, cCAM Biotherapeutics Ltd operates as a subsidiary of Merck & Co. Inc.

MedCPU Inc. develops real-time enterprise decision support software aimed at enhancing clinical care in hospitals across the United States. Founded in 2008 and based in New York, the company offers the medCPU Advisor platform, which integrates patient profiles derived from both structured and unstructured data. Its innovative Advisor Button technology captures and analyzes clinical information from clinicians’ free-text notes, dictations, and structured documentation entered into electronic medical records (EMRs). This analysis is conducted against an extensive library of medical content, allowing the platform to generate precise, real-time prompts for care consideration, as well as providing clinical and compliance guidance. MedCPU's focus is on improving decision-making processes in healthcare settings through advanced data integration and analysis.

OpGen, Inc. is a precision medicine company based in Gaithersburg, Maryland, that specializes in developing molecular diagnostics and informatics aimed at combating infectious diseases. The company offers a range of products, including the Acuitas AMR Gene Panel, which detects bacterial nucleic acids and antimicrobial resistance markers, and QuickFISH and PNA FISH tests for identifying pathogens in blood cultures. Additionally, OpGen provides the Acuitas Lighthouse informatics system, a cloud-based platform that integrates clinical lab results with patient data to help manage multidrug-resistant organisms in healthcare settings. Through its strategic collaboration with the New York State Department of Health, OpGen is working on solutions to detect and manage antimicrobial-resistant infections in healthcare facilities. The company's innovative technologies are utilized by academic, government, and research institutions globally for applications such as strain typing and genome assembly. OpGen aims to enhance patient care and outcomes while addressing the growing challenge of antibiotic resistance.

Spero Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializes in developing novel therapies for multi-drug resistant (MDR) bacterial infections and rare diseases. Its key product candidates include tebipenem pivoxil hydrobromide, an oral carbapenem-class antibiotic intended for adults with MDR Gram-negative infections, and SPR206, an intravenous agent targeting MDR Gram-negative infections in hospital settings. Additionally, the company is advancing SPR720, an oral antibiotic designed for treating pulmonary non-tuberculous mycobacterial disease. Spero Therapeutics has established various collaborations and license agreements to support the development and commercialization of its products, including partnerships with Meiji Seika Pharma, Everest Medicines, and the Bill & Melinda Gates Medical Research Institute. Founded in 2013, Spero aims to address the critical need for effective treatments against serious bacterial infections using innovative approaches and mechanisms.

Koneksa Health Inc. is a healthcare data analytics company based in New York, with an additional location in London. Founded in 2013, the company specializes in designing and developing software for pharmaceutical and biotech firms to facilitate decision-making and regulatory claims based on remotely generated patient data. Its flagship product, Koneksa Compare, provides a dashboard for capturing, monitoring, and analyzing patient-generated data and outcomes in clinical studies. The software supports the integration of emerging technologies, such as bio-sensors, activity trackers, and mobile-based questionnaires, allowing researchers to expand the range of analyzable data and reduce subjectivity in clinical endpoints. Koneksa Health aims to enhance the efficiency and accuracy of clinical research through its innovative solutions.

NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapeutics for various diseases, including cardio-metabolic, liver, oncologic, and ophthalmic conditions. The company is advancing several product candidates, such as Aldafermin, currently in Phase 2b trials for non-alcoholic steatohepatitis (NASH), and NGM313, an antibody in Phase 1b trials aimed at treating type 2 diabetes and NASH. Other notable candidates include NGM395 for metabolic syndrome, NGM120 targeting cancer anorexia/cachexia syndrome, NGM217 to enhance insulin production in diabetes patients, and NGM621 for addressing dry age-related macular degeneration. Founded in 2007 and headquartered in South San Francisco, NGM Biopharmaceuticals is committed to leveraging insights from human clinical and genetic studies to develop transformative therapies, particularly focusing on the gastrointestinal endocrine system and its role in metabolic diseases. The company collaborates with Merck Sharp & Dohme Corp for research and product development initiatives.

Daktari Diagnostics, Inc., a healthcare solutions company, develops and provides portable point-of-care diagnostic platforms for disease management Worldwide. It offers Daktari Virology, a platform for HCV and HIV detection; Daktari InSight, a data management service that connects Daktari’s systems to its customers; and Daktari Sickle Cell, a solution that provides tests to identify infants with sickle cell disease from a drop of blood. The company was founded in 2008 and is based in Cambridge, Massachusetts.

Cubist Pharmaceuticals is a biopharmaceutical company dedicated to the research, development, and commercialization of innovative therapies aimed at addressing unmet medical needs in acute care settings. The company is known for marketing CUBICIN (daptomycin for injection), a groundbreaking antibiotic in the lipopeptide class, as well as ENTEREG (alvimopan), which facilitates gastrointestinal recovery after certain surgeries. Cubist also promotes MERREM I.V. (meropenem for injection), an established antibiotic developed by AstraZeneca. Its product pipeline includes ecallantide, currently in Phase 2 clinical trials, and ongoing research focused on reducing blood loss during cardiac surgery. Additionally, the company is exploring treatments for Clostridium difficile-associated diarrhea and multi-drug resistant Gram-negative infections. In collaboration with Alnylam Pharmaceuticals, Cubist is also developing novel therapies for respiratory syncytial virus infections using RNA-interference technology. Founded in 1992 and headquartered in Lexington, Massachusetts, Cubist Pharmaceuticals continues to advance its mission of improving patient outcomes in acute care environments.

Preventice Inc. develops mobile health applications and patient monitoring systems that connect mobile, home-based, and on-premise technologies for continuous patient care. It offers HealthClips Rx, an interactive patient education platform that feeds data about patient compliance and post-surgical complications back into the clinical system; and CARD-Contact Allergen Replacement Database, which provides people with skin allergies access to information about products that contain known allergens. The company also provides Coppertone MyUVAlert that helps people avoid overexposure to the sun; and iManage Migraine, an application that helps people to track and understand what triggers their migraine headaches. In addition, it offers care plan management, patient education, remote monitoring, relationship management, and integrated analytics solutions. Preventice Inc. was formerly known as Boost Information Systems, Inc. The company was founded in 2007 and is based in Rochester, Minnesota with additional offices in Fargo, North Dakota.

Healthsense, Inc. specializes in remote monitoring services aimed at the senior care continuum. Founded in 2001 and based in Mendota Heights, Minnesota, the company provides health and safety monitoring solutions that track essential daily activities such as eating, sleeping, and movement. Their technology includes analytics that transform data into actionable insights, a centralized dashboard for caregivers, health notes to alert changes in behavior, and real-time notifications for urgent needs. These features help caregivers respond effectively to the needs of seniors, enhancing their independence and overall quality of life. Healthsense serves various markets, including senior living, managed care, and home care, and operates as a subsidiary of GreatCall, Inc. since December 2016.

Cleveland HeartLab, Inc. is a clinical reference laboratory dedicated to the prevention of cardiovascular disease (CVD) through innovative biomarker technologies and proprietary diagnostic tests. The company specializes in the early identification of individuals at risk for CVD, emphasizing the management and reduction of inflammation. Cleveland HeartLab provides a range of clinical laboratory services, including an inflammatory panel for CVD, an advanced CVD risk profile, and lipid testing. By focusing on novel molecular biomarkers, the company aims to enhance disease management and improve patient outcomes in cardiovascular health.

MedCPU Inc. develops real-time enterprise decision support software aimed at enhancing clinical care in hospitals across the United States. Founded in 2008 and based in New York, the company offers the medCPU Advisor platform, which integrates patient profiles derived from both structured and unstructured data. Its innovative Advisor Button technology captures and analyzes clinical information from clinicians’ free-text notes, dictations, and structured documentation entered into electronic medical records (EMRs). This analysis is conducted against an extensive library of medical content, allowing the platform to generate precise, real-time prompts for care consideration, as well as providing clinical and compliance guidance. MedCPU's focus is on improving decision-making processes in healthcare settings through advanced data integration and analysis.

AdvanDx, Inc. is a biotechnology company based in Woburn, Massachusetts, specializing in molecular diagnostic tests for identifying pathogens responsible for critical infections in hospitalized patients. Founded in 2002, the company focuses on improving patient outcomes by facilitating earlier antibiotic therapy through rapid pathogen identification. AdvanDx offers a range of products, including QuickFISH and PNA FISH tests for detecting bacteria and yeast from positive blood cultures, as well as XpressFISH for identifying resistance markers. Its PNA Probes target ribosomal RNA sequences in bacteria and fungi. The company provides its diagnostic solutions to medical centers, reference laboratories, government institutions, and community hospitals, distributing its products through a network of sales representatives and international distributors. AdvanDx has operated as a subsidiary of OpGen, Inc. since 2015.

WellDoc, Inc. is a digital health company focused on chronic disease management, particularly diabetes care. Founded in 2005 and headquartered in Baltimore, Maryland, WellDoc offers innovative solutions such as the DiabetesManager platform and BlueStar mobile prescription therapy. The DiabetesManager platform facilitates patient-provider coordination through features like personalized coaching, medication reminders, and real-time alerts, while BlueStar offers patients immediate guidance to enhance self-management of diabetes. WellDoc’s services also include clinical decision support for healthcare professionals and a comprehensive suite of technical services, such as software development and regulatory management. The company aims to improve health outcomes and reduce healthcare costs by integrating behavioral and motivational applications with everyday technology. WellDoc serves a diverse range of clients, including payors, employers, pharmaceutical and medical device companies, and healthcare providers.

GenomeDx discovers, develops, and commercializes genomic-based laboratory tests for the personalized medicine revolution in cancer care. In partnership with physicians and scientists from leading academic medicine institutions, our mission is to bring cost-effective and high-resolution genomics for routine clinical use in cancer medicine.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

Humedica is the clinical intelligence company that powers health care providers and life sciences organ izations to make better-informed, more confident decisions by transforming unconnected data from multiple sources into real-world insights.

Prognos Health is a prominent health tech company specializing in healthcare analytics aimed at improving disease management and treatment decision-making. Its platform, prognosFACTOR, allows users to quickly query billions of lab and health records from over 325 million de-identified patients, significantly reducing the time needed to answer critical healthcare questions. The Prognos Registry serves as the largest source of clinical diagnostics information across more than 30 disease areas, encompassing over 5 billion medical records for 100 million patients. By employing a suite of 500 proprietary clinical algorithms, Prognos facilitates earlier patient identification, enhancing treatment decisions and risk management. The company collaborates with key stakeholders in the healthcare ecosystem, including pharmaceutical manufacturers and payers, providing HIPAA-compliant patient-centric data through the Prognos Marketplace for various applications such as cohort design and health outcomes analysis.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

eHealth Technologies™ (formerly eHealth Global) is a healthcare digital services company focused on retrieving, digitizing, storing, securing, and providing access to patient medical records. eHealth Technologies™ utilizes a processes to retrieve, secure, store, transmit, and present patient data to healthcare providers.

Healthsense, Inc. specializes in remote monitoring services aimed at the senior care continuum. Founded in 2001 and based in Mendota Heights, Minnesota, the company provides health and safety monitoring solutions that track essential daily activities such as eating, sleeping, and movement. Their technology includes analytics that transform data into actionable insights, a centralized dashboard for caregivers, health notes to alert changes in behavior, and real-time notifications for urgent needs. These features help caregivers respond effectively to the needs of seniors, enhancing their independence and overall quality of life. Healthsense serves various markets, including senior living, managed care, and home care, and operates as a subsidiary of GreatCall, Inc. since December 2016.

Remedy Informatics, formerly known as RemedyMD, is a prominent provider of patient registries and medical research software designed to enhance the efficiency of translational medicine. The company specializes in developing meta-registries and clinical informatics systems that aid scientific researchers by utilizing predictive informatics to identify patterns, personalize treatment, and integrate diverse data types. Built on the Mosaic™ Platform, Remedy's offerings are highly configurable, supporting various healthcare and life science research initiatives. The company's mission focuses on significantly improving the effectiveness of research, aiming to yield tangible outcomes in healthcare advancements globally.

Healthsense, Inc. specializes in remote monitoring services aimed at the senior care continuum. Founded in 2001 and based in Mendota Heights, Minnesota, the company provides health and safety monitoring solutions that track essential daily activities such as eating, sleeping, and movement. Their technology includes analytics that transform data into actionable insights, a centralized dashboard for caregivers, health notes to alert changes in behavior, and real-time notifications for urgent needs. These features help caregivers respond effectively to the needs of seniors, enhancing their independence and overall quality of life. Healthsense serves various markets, including senior living, managed care, and home care, and operates as a subsidiary of GreatCall, Inc. since December 2016.

Mihealth Global Systems, Inc. is a Toronto-based company that develops a healthcare messaging system designed to facilitate bi-directional communication between patients and physicians. Founded in 2009 by Dr. Wendy Graham, the mihealth application provides patients with secure online access to their physician-validated health information, enabling them to manage and organize their health data effectively. This interactive mobile technology enhances communication and allows physicians to stay updated on their patients' medical histories. By simplifying the connection between patients and healthcare providers, mihealth empowers individuals to take control of their health and wellness through accessible and user-friendly tools available on smartphones and tablets.

Daktari Diagnostics, Inc., a healthcare solutions company, develops and provides portable point-of-care diagnostic platforms for disease management Worldwide. It offers Daktari Virology, a platform for HCV and HIV detection; Daktari InSight, a data management service that connects Daktari’s systems to its customers; and Daktari Sickle Cell, a solution that provides tests to identify infants with sickle cell disease from a drop of blood. The company was founded in 2008 and is based in Cambridge, Massachusetts.

Aviir is a venture-funded biotechnology company developing cutting-edge, diagnostic tests enabling accurate diagnosis and prognosis of cardiovascular disease. The company’s proprietary technology is based on ten years of research at Stanford University, and combines the scientific founder’s deep understanding of biomarker assay development and advanced biostatistics. Aviir has pursued an aggressive commercialization strategy, and initial products, including the MIRISK VP™ test, are currently on the market. The Aviir leadership team includes the founding scientists and highly experienced management.

HTG Molecular Diagnostics is a commercial stage life sciences company based in Tucson, Arizona, specializing in precision medicine. The company develops and markets molecular-based technology solutions for gene expression profiling and the measurement of miRNA, siRNA, and mRNA, which are essential for translational medicine and diagnostic applications. HTG offers a range of instrumentation, assay kits, and software that automate sample processing and analyze various molecular targets. Its platforms create molecular profiling libraries for next-generation sequencing, with marketed panels including oncology biomarker panels and immuno-oncology assays. HTG serves biopharmaceutical companies, academic research centers, and molecular testing laboratories, distributing its products directly within the United States and Europe, as well as through distributors in other regions. The company is also engaged in collaborations for the development of RNA and DNA profiling tests, enhancing its role in the evolving landscape of molecular diagnostics.

Preventice Inc. develops mobile health applications and patient monitoring systems that connect mobile, home-based, and on-premise technologies for continuous patient care. It offers HealthClips Rx, an interactive patient education platform that feeds data about patient compliance and post-surgical complications back into the clinical system; and CARD-Contact Allergen Replacement Database, which provides people with skin allergies access to information about products that contain known allergens. The company also provides Coppertone MyUVAlert that helps people avoid overexposure to the sun; and iManage Migraine, an application that helps people to track and understand what triggers their migraine headaches. In addition, it offers care plan management, patient education, remote monitoring, relationship management, and integrated analytics solutions. Preventice Inc. was formerly known as Boost Information Systems, Inc. The company was founded in 2007 and is based in Rochester, Minnesota with additional offices in Fargo, North Dakota.

SmartCells, Inc. designs and develops insulin products. It offers SmartInsulin, a self regulating injectable formulation for treating diabetes. The company's polymer-based dosing technology is used for various applications, such as fertility, thyroid, and growth hormone deficiencies; treatments with poor compliance or therapeutic window issues, such as oncology; and drug-device combinations. SmartCells, Inc. was founded in 2003 and is based in Beverly, Massachusetts.

HTG Molecular Diagnostics is a commercial stage life sciences company based in Tucson, Arizona, specializing in precision medicine. The company develops and markets molecular-based technology solutions for gene expression profiling and the measurement of miRNA, siRNA, and mRNA, which are essential for translational medicine and diagnostic applications. HTG offers a range of instrumentation, assay kits, and software that automate sample processing and analyze various molecular targets. Its platforms create molecular profiling libraries for next-generation sequencing, with marketed panels including oncology biomarker panels and immuno-oncology assays. HTG serves biopharmaceutical companies, academic research centers, and molecular testing laboratories, distributing its products directly within the United States and Europe, as well as through distributors in other regions. The company is also engaged in collaborations for the development of RNA and DNA profiling tests, enhancing its role in the evolving landscape of molecular diagnostics.

PHT Corporation is a leading provider of electronic patient-reported outcome (ePRO) solutions utilized in clinical trials globally. The company offers the LogPad and StudyPad Systems, which enhance data quality and facilitate efficient data collection. Additionally, PHT's StudyWorks online portal grants study sponsors, monitors, and sites real-time access to trial data, enabling informed decision-making. By leveraging these technologies, biopharmaceutical and medical device companies can obtain more comprehensive data and accelerate their trial processes, ultimately contributing to the success of clinical studies.

VisEn Medical, Inc. specializes in the design, development, and commercialization of fluorescence in vivo imaging technology platforms. The company focuses on its Fluorescence Molecular Tomographic (FMT) imaging systems and various vivo imaging agents that enhance the identification, characterization, and quantification of disease biomarkers and therapeutic efficacy in living organisms. Among its notable products are ReninSense680, an imaging agent used for monitoring hypertension and renal disease biomarkers, and VivoTagR 680 XL, a fluorescent dye suitable for labeling biomolecules in diverse in vitro and in vivo imaging applications. Additionally, VisEn Medical provides advanced fluorescence tomographic imaging systems to support its imaging technology offerings.

HTG Molecular Diagnostics is a commercial stage life sciences company based in Tucson, Arizona, specializing in precision medicine. The company develops and markets molecular-based technology solutions for gene expression profiling and the measurement of miRNA, siRNA, and mRNA, which are essential for translational medicine and diagnostic applications. HTG offers a range of instrumentation, assay kits, and software that automate sample processing and analyze various molecular targets. Its platforms create molecular profiling libraries for next-generation sequencing, with marketed panels including oncology biomarker panels and immuno-oncology assays. HTG serves biopharmaceutical companies, academic research centers, and molecular testing laboratories, distributing its products directly within the United States and Europe, as well as through distributors in other regions. The company is also engaged in collaborations for the development of RNA and DNA profiling tests, enhancing its role in the evolving landscape of molecular diagnostics.

NovaCardia is a product-focused pharmaceutical company with significant capabilities and experience in cardiovascular drug development. The company is committed to improving the quality of care for patients with cardiovascular disease by developing and commercializing a portfolio of novel small molecule drugs. NovaCardia will be focused initially on the acute cardiac care marketplace.

Abmaxis, Inc., a biopharmaceutical company, engages in the discovery, optimization, and development of monoclonal antibody (MAb) products for human therapeutics and diagnostics.

PHT Corporation is a leading provider of electronic patient-reported outcome (ePRO) solutions utilized in clinical trials globally. The company offers the LogPad and StudyPad Systems, which enhance data quality and facilitate efficient data collection. Additionally, PHT's StudyWorks online portal grants study sponsors, monitors, and sites real-time access to trial data, enabling informed decision-making. By leveraging these technologies, biopharmaceutical and medical device companies can obtain more comprehensive data and accelerate their trial processes, ultimately contributing to the success of clinical studies.

PHT Corporation is a leading provider of electronic patient-reported outcome (ePRO) solutions utilized in clinical trials globally. The company offers the LogPad and StudyPad Systems, which enhance data quality and facilitate efficient data collection. Additionally, PHT's StudyWorks online portal grants study sponsors, monitors, and sites real-time access to trial data, enabling informed decision-making. By leveraging these technologies, biopharmaceutical and medical device companies can obtain more comprehensive data and accelerate their trial processes, ultimately contributing to the success of clinical studies.

Medco Containment Services Inc., one of the largest mail-order pharmacy and managed-care drug companies.